Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte Highlights Innovations in Scalable, High-Throughput Transfection for Cell-Based Assays & Protein Production at the SLAS2012 Conference and Exhibition in San Diego, Booth #848
February 7, 2012
MaxCyte Presents Joint Data with Sophion, Corning, and Codex BioSolutions Demonstrating Unmatched Cell Compatibility and Applications in Cell Based Assays and Gram Scale Protein & Antibody Production
Gaithersburg, Maryland - MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, is hosting a series of events at the 1st Annual Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition to be held February 4-8, 2012, in San Diego, CA. MaxCyte will present scientific posters, conduct a tutorial, and schedule one-on-one discussions in Booth #848 to demonstrate how the MaxCyte Scalable Transfection Systems can improve the physiological relevance and quality of cellular screening campaigns and can increase the efficiency and yield of protein and antibody production.
At the conference, MaxCyte will conduct a tutorial entitled "Accelerated Cell-Based Screening Using MaxCyte Large Volume Transient Transfection: MaxCyte Synergy with Sophion QPatch and Codex ACTOne High Throughput Assays" on Tuesday, February 7, at 12:30 PM in Room 5A at the San Diego Convention Center. In this tutorial, Dr. Chris Mathes, Vice President and General Manager, North America, of Sophion Bioscience, Inc., will present case studies demonstrating the use of the MaxCyte STX in conjunction with the Sophion QPatch for evaluating sodium and potassium ion channel activity. In addition, Dr. James Brady, Director of Technical Applications at MaxCyte, will present specific case studies demonstrating the broad cell type compatibility of the MaxCyte STX, including stem cells, primary cells, insect cells, and other difficult-to-transfect cell lines, along with the performance of these transfected cells in downstream applications for cell-based screening and protein production. Highlighted in Dr. Brady's presentation will be the complementary performance of the MaxCyte flow electroporation technology with the innovative Codex BioSolutions ACTOne platform for screening GPCR targets.
MaxCyte will also present two scientific posters entitled, "Rapid generation of cells for ion channel assays: efficient, large-scale transfection using the MaxCyte® STX™ System, convenient cell culture using Corning® HYPERflasks™, and robust target activity assayed by the Sophion QPatch" (poster #MP81) and "Enabling rapid and sensitive GPCR assay development with the MaxCyte STX Scalable Transfection System and the Codex ACTOne biosensor technology" (poster #MP100). MaxCyte scientists will be available at these posters on Monday, February 6, 2012, from 1:00 to 3:00 PM for further discussion of these data.
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte® STX™ Scalable Transfection System and MaxCyte® VLX™ Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot scale.